Abstract
There is evidence that aspirin is partially effective in the prophylaxis of various vasoocclusive disorders. This article reviews pharmacologic opportunities for improvement over and above the therapeutic effect of aspirin. It is concluded that several rational possibilities merit consideration, in particular, the use of combinations of drugs that affect the thrombotic process at different points. Such strategies will ultimately require validation by clinical trial.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference43 articles.
1. Functional properties of an endothelial cell cofactor for thrombin catalysed activation of prote;Owen WC;C. J Biol Chem,1981
2. Molecular Heterogeneity of Inherited Antithrombin III Deficiency
3. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant.
4. Dollery CT Bulpitt CJ: Management of hypertension. In Genest J. Koiw E Kuchel 0 editors: Hypertension. New York 1977 McGraw-Hill pp 1038-1068
5. Oliver MF: Trials of lipid lowering drugs in coronary prevention. In Miller NE editor: Atherosclerosis mechanisms and approaches to therapy. New York 1984 Raven Press
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献